key: cord-0931663-5o8u20e1 authors: Hughes, E.; Binny, R. N.; Hendy, S.; James, A. title: Predicting elimination of evolving virus variants date: 2021-06-25 journal: nan DOI: 10.1101/2021.06.24.21259501 sha: cedf18202a923f621e7f9b2b88c278bc8a76a0d8 doc_id: 931663 cord_uid: 5o8u20e1 As the SARS-CoV-2 virus spreads around the world new variants are appearing regularly. Although some countries have achieved very swift and successful vaccination campaigns, on a global scale the vast majority of the population is unvaccinated and new variants are proving more resistant to the current set of vaccines. We present a simple model of disease spread which includes the evolution of new variants and varying vaccine effectiveness to these new strains. We show that rapid vaccine updates to target new strains are more effective than slow updates and containing spread through non-pharmaceutical interventions is vital whilst these vaccines are delivered. Finally when measuring the key model inputs, e.g. the rate at which new mutations and variants of concern emerge, is difficult we show how an observable model output, the number of new variants which have been seen, is strongly correlated with the probability the virus is eliminated. The recent emergence of multiple SARS-CoV-2 variants poses a risk to the global efforts to control 21 the COVID-19 pandemic. In the short term the increased transmissibility of some variants raises the 22 risk of uncontrolled outbreaks (Davies et al., 2021; Tegally et al., 2020) . In the long term, the 23 increasing genetic diversity of the virus may result in reduced vaccine efficacy due to immune escape, 24 i.e. variants may mutate so that antibodies which target other variants cannot successfully bond to simplifying assumption which is no longer accurate. Here we construct a simple stochastic branching 29 process model for multi-strain epidemics of COVID-19. By simulating outbreaks under different 30 assumptions, we suggest some possible dynamics for genetic diversity and propose observable 31 measures to assess the effect of these multiple strains on long term elimination. 32 Genomic data of the Sars-CoV-2 virus has been widely shared worldwide. Although RNA viruses in 33 general tend to mutate quickly, coronaviruses in particular mutate much slower, likely due to a proof-34 reading enzyme that corrects copying mistakes which are potentially fatal to the virus. Although 12,000 35 mutations were spotted in Sars-CoV-2 within a year of its emergence almost all of these appeared to 36 have almost no consequence on the virus's transmission rate (Callaway, 2020) . 37 The mutation rate of a virus can be thought of on many levels. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table S1 gives details of the administration and uptake of vaccines in different countries, and the 77 incidence of each VoC (as a proportion of all sequenced infected cases) . As of early April all countries 78 with a significant number of infections had significant numbers of infections by at least one VoC. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) April 2021 varied between <0.1% of the population daily, e.g. New Zealand, and over 0.8% of the 82 population daily, e.g. UK and USA. The proportion of the population who are likely to be vaccinated 83 ranges from less than 50% (USA) to over 75% (NZ, Brazil). 84 Our model tracks virus mutations at a rate somewhere between the two extremes, we assume there variants. 96 We explore the model and give results on how the probability of elimination changes as the speed at 97 which vaccines are rolled out is increased for different cross-immunity and mutation rate scenarios. 98 Finally, we discuss how to estimate the probability of elimination in a system where the key 99 parameters are not known. where is a normally distributed random variable, ~(0,1). We cap at a maximum rate . 129 This assumes that transmission rates will be self-limiting as social distancing measures imposed Immunity model Once an individual has been infected with variant of the virus they naturally acquire 139 full immunity to that variant. However, they may still become infected by a different stain of the virus. 140 The probability that an individual who has been infected with variant is immune to variant is . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It also confers partial immunity against other variants following the same rules as the natural Table 1 for high cross-immunity between strains and low transmission = 0.005. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1. 221 222 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 25, 2021. Results -Vaccines available 223 We now analyse the model results when a vaccine is available and can be updated to target new and 224 emerging variants. We assume the first vaccine is available 350 days after the first infections and In the Continuous strategy presented in Figure 3 , the updated vaccine is given to the next individual 263 on the priority list. This means lower priority individuals will likely receive the new vaccine first but 264 every individual in the population will be vaccinated before the first individual receives their second 265 vaccination, i.e. the higher priority individuals will only receive a vaccine update after all the other 266 individuals have been vaccinated. We compare this to a Restart strategy where each new vaccine is 267 given to individuals at the start of the priority list first, i.e. high priority individuals will receive every 268 new vaccine as soon as it is available, while low priority individuals may never be vaccinated. Figure 4 269 shows that in all four transmission and cross-immunity scenarios the probability of elimination is Vaccine uptake rate and effectiveness 284 Previous results assume that all individuals who are offered a vaccine will take it whereas Table S1 285 shows that in most countries uptake rates fall between 40% and 70%. As these rates are for the adult 286 population and paediatric vaccines are often developed later than adult ones the actual uptake rate 287 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The results so far are shown for a relatively small population of only 10,000 individuals. Whilst this is 307 computational cheaper it is less realistic. For the same reasons the results are constrained to relatively 308 low maximum transmission rates. Figure 6 shows the output for a more realistic set of parameter 309 values with population sizes up to 500,000, a higher maximum transmission rate = 3, vaccine 310 uptake rate of 60%, delivery rate of 1% of the population each day and vaccines are updated every 311 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. where is the number of significant variants seen in that realisation during the first 300 days, 330 is the mutation rate, is the population size and is the level of cross-immunity defined 331 as a linear scaling on all the elements of ( ) in Table 2 . Using all available predictor variables results 332 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 25, 2021. ; https://doi.org/10.1101/2021.06.24.21259501 doi: medRxiv preprint Page | 14 in a highly accurate prediction of elimination probability (area under the receiver operator curve 333 = 0.97, Table 3 ). However, more encouragingly, using a simpler model with only the single 334 predictor gives a very good prediction of elimination probability ( = 0.94, Table 3 ). 335 (1) log ( ) log( ) AUC 68%. Using the more detailed predictor model shows that for any given number of additional 341 significant variants the probability of elimination will decrease for bigger populations, lower cross-342 immunity and faster mutation rates. 343 Here we used the number of variants that arise in the first 300 days after the virus emerged. Very 344 similar results can be seen for other time periods. When more than two or three significant new 345 strains of the virus have emerged the probability of elimination drops significantly. 346 Sensitivity analysis 347 We used a numerical definition of elimination where any realisation that reached 200 variants was 348 assumed to continue indefinitely. This was checked extensively throughout the study and was seen 349 to be correct in over 97% of realisations even for higher population sizes. 350 We have assumed a 100% vaccine effectiveness rate for the strain for which the vaccine was 351 developed. Although we have not changed this explicitly the results of doing so would look very 352 similar to the results for a lower uptake rate. For example the results for a 50% effective vaccine 353 delivered at a rate of 1% of the population each day would be very similar to those for a 100% effective 354 vaccine with an uptake rate of 50% delivered at a speed of 0.5% of the population each day. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 25, 2021. ; https://doi.org/10.1101/2021.06.24.21259501 doi: medRxiv preprint Immune evasion means we need a 404 new COVID-19 social contract Canalization of the evolutionary trajectory of the human 406 influenza virus The coronavirus is mutating-does it matter? Fast-spreading COVID variant can elude immune responses SARS-CoV-2 Variant Classifications and Definitions Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England Global dynamics of SARS-CoV-2 clades 414 and their relation to COVID-19 epidemiology A structured model 416 for COVID-19 spread: modelling age and healthcare inequities A structured model 418 for COVID-19 spread: modelling age and healthcare inequities Understanding the dynamics of rapidly evolving pathogens 420 through modeling the tempo of antigenic change: influenza as a case study A two-tiered model for simulating the ecological and 422 evolutionary dynamics of rapidly evolving viruses, with an application to influenza Capturing the dynamics of pathogens with many strains Mathematical biology: I. An introduction Phylogenetic and phylodynamic analyses of 428 SARS-CoV-2 Sensitivity 430 of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus CoV-2) lineage with multiple spike mutations in South Africa. medRxiv United Nations, Department of Economic and Social Affairs, Population Division COVID-19 weekly epidemiological update International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 25, 2021. ; https://doi.org/10.1101/2021.06.24.21259501 doi: medRxiv preprint We have assumed that the first vaccine to be developed takes approximately one year of 356 development time. Explorations show that improving this initial development speed would increase 357 the probability of elimination overall but the qualitative differences in results for changing other 358 parameters would not change significantly. 359 Changing the disease transmission parameters, e.g. the number of infectious days does not change 360 the overall results but does give a corresponding change in the timescale. Significant changes come 361 with changing the transmission rates but these are explored through changes to , the maximum 362 transmission rate. 363 Although cross immunity was varied in the results we assumed a linear scaling of cross-immunity 364 across all distances in the virus tree. If cross-immunity remains high for closely related variants but 365 decreases more rapidly with the network distance between variants this has a similar effect as lower 366 overall cross-immunity. Under high vaccination rates, our results highlight the importance of ensuring that vaccine uptake 380 rates are kept above the herd immunity threshold to avoid a considerable reduction in elimination 381 probability. However, at lower vaccination rates this factor has less impact on the probability of 382 elimination, which is low regardless. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.